ArticleNeuroprotection (Chichester, England)2026
Effectiveness and safety of efgartigimod in patients with anti-NMDAR or anti-LGI1 encephalitis and its
Article in Neuroprotection (Chichester, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Efgartigimod disrupts the recycling of pathogenic IgG autoantibodies and may represent a candidate therapy for autoimmune encephalitis. This real-world study evaluated the clinical efficacy, safety, and impact of efgartigimod on brain inflammation. Methods: This multicenter, single-arm, prospective, observational real-world study enrolled 18 patients, including 10 with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis and 8 with anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. Participants received intravenous efgartigimod at a dose of 10 mg/kg weekly for a total of two to four doses, with or without concomitant immunosuppressive therapy. Anti-NMDAR-IgG/LGI1-IgG antibody titers, modified Rankin scale (mRS), Clinical Assessment Scale in Autoimmune Encephalitis (CASE), Montreal Cognitive Assessment, Mini-Mental State Examination, and Glasgow Coma Scale scores were assessed at baseline and at 1, 2, 3, 8, and 12 weeks after treatment. Results: At the final follow-up, median mRS scores in patients with anti-NMDAR encephalitis decreased significantly from 3 (range, 1-5) before treatment to 1 (range, 0-3) after treatment ( Conclusion: Efgartigimod may represent a novel therapeutic option for anti-NMDAR and anti-LGI1 encephalitis, potentially improving clinical outcomes in affected patients. Registration Info: This study was registered at the National Clinical Research Center (https://www.medicalresearch.org.cn; No. MR-31-24-053225).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.